Jaap Goudsmit
From Wikipedia, the free encyclopedia
 |
This article may require cleanup to meet Wikipedia's quality standards. Please improve this article if you can. (September 2007) |
Jaap Goudsmit (born in Amsterdam, 22 July 1951)
Professor of Poverty-related Communicable Diseases
Chairman of the Board
Academic Medical Center/University of Amsterdam
Amsterdam, the Netherlands
Aids Foundation East-West (AFEW)
Chairman of the Board
Moscow, Russian Federation
Jaap Goudsmit MD PhD,received his MD degree from the Faculty of Medicine of the University of Amsterdam in 1978 and his PhD degree from the same university in 1982.
In 1978 he was awarded a Fogarty fellowship and in 1982 a Fogarty visiting scientist award to postdoctoral research at the National Institutes of Health in Bethesda, Maryland USA. In 1983 Jaap Goudsmit was board certified in the Netherlands as a Medical Microbiologist.
Jaap Goudsmit, has been head of the Department of Human Retrovirology at the Academic Medical Center (AMC) of the University of Amsterdam from 1996 to 2002 and chairman of the AMC Research Institute for Infectious Diseases and the AMC Institute for Science Education. Since 1984 he is one of the principal investigators of the Amsterdam Cohort Studies of homosexual men and IV drug users. He is the founder of PrimaGen, the first biotech company concentrating on predictive medicine. He chaired the Scientific Advisory Committee of the International AIDS Vaccine Initiative (IAVI) and has been a member of its board. He was project leader and (co)chair of Eurovac.
In 2002, Jaap Goudsmit joined Crucell, a leading biotechnology company in Leiden, as Chief Medical Officer and Executive Vice President of Vaccine Research and Development. In 2003 he was elected as member of the HIV Vaccine Enterprise Product Development Working Group of the Gates Foundation and in 2006 he is affiliated with Pevion as member of the Supervisory Board. In 2006 Jaap Goudsmit entered the board of Vaxin Inc.
